Core Viewpoint - A class action lawsuit has been filed against Krispy Kreme, alleging that the company made false statements regarding its partnership with McDonald's and the demand for its products, leading to significant financial losses for investors [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Krispy Kreme securities between March 26, 2024, and May 7, 2025 [1]. - Investors have until July 15, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. - The lawsuit claims that demand for Krispy Kreme products declined significantly at McDonald's locations after the initial marketing launch [3]. Group 2: Financial Performance - Krispy Kreme reported net revenue of $375.2 million for the first quarter of 2025, representing a decline of 15.3% compared to the previous year [4]. - The company also reported a net loss of $33.4 million, compared to a net loss of $6.7 million in the prior year [4]. - Following the release of these financial results, Krispy Kreme's share price fell by nearly 25% [4]. Group 3: Partnership with McDonald's - Krispy Kreme and McDonald's expanded their partnership nationwide starting in the second half of 2024, following a small-scale test in 2022 [2]. - The lawsuit alleges that the partnership was not profitable and posed a substantial risk to maintaining the collaboration with McDonald's [3]. - Krispy Kreme announced it is reassessing its deployment schedule with McDonald's and has withdrawn its prior full-year outlook due to uncertainty around the partnership [4].

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) on behalf of PetMed stockholders. Our investigation concerns whether PetMed has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On June 10, 2025, PetMed issued a press release "announc[ing] it is d ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bausch + Lomb Corporation (“Bausch & Lomb” or the “Company”) (NYSE:BLCO) on behalf of Bausch & Lomb stockholders. Our investigation concerns whether Bausch & Lomb has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On March 27, 2025, Bausch & Lomb announced a v ...

Reiterate Commitment to Fight for Liquidity and Transparency Against Entrenched Incumbents Set Record Straight on Ionic’s Most Recent Misleading Statements Urge Their Fellow Stockholders to Learn More About Their Plan for Change at www.ionicvote.com SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Tony Vejseli, Chris Villinger, and Brett Perry (the “Concerned Stockholders”), stockholders of Ionic Digital Inc. (“Ionic” or the “Company”), today issued a public letter to their fellow stockholders announcing th ...

Core Viewpoint - Fortrea has adopted a limited-duration stockholder rights plan to protect the long-term value for all stockholders and ensure fair treatment in potential takeover situations [1][2][3] Summary by Sections Rights Plan Purpose - The Rights Plan aims to enable stockholders to realize long-term investment value and ensure fair treatment during any proposed takeover [2] - It is designed to prevent tactics that could allow control of the Company without appropriate compensation to all stockholders [2] - The plan was initiated in response to significant dislocation in the trading price of the Company's stock and interest from third parties to capitalize on this dislocation [2] Rights Plan Details - The Rights Plan applies equally to all current and future stockholders and does not deter offers or preclude the Board from considering beneficial transactions [3] - Fortrea will issue one right for each share of common stock as of June 23, 2025, with rights becoming exercisable if any person acquires 10% or more of the outstanding common stock [4] - If exercisable, rights holders (excluding the triggering person) can acquire shares at a 50% discount or exchange rights for one share of common stock [4] - The Board can redeem the rights at $0.001 per right, and the plan does not limit future Boards' ability to redeem the rights [4] Company Overview - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [6] - The Company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [6]

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Turtle Beach Corporation (Nasdaq: TBCH, the “Company”), a leading gaming accessories brand, today announced that its Board of Directors (the “Board”) has approved the adoption of a limited duration stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one right (“Right”) for each outstanding share of common stock. The record date for such dividend distribution is June 23, 2025. The adoption of the Rights Plan is intended to enable al ...

Core Viewpoint - Ichor Holdings, Ltd. is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results in Q1 2025, which led to a significant drop in stock price [1][2]. Financial Performance - On May 5, 2025, Ichor reported its Q1 2025 financial results, missing both EPS and revenue consensus estimates [2]. - The company reported a gross margin of 12.4%, which is below the forecasted midpoint of 14.5% [2]. - Ichor attributed the margin shortfall to purchasing more external supply than anticipated, which did not translate into expected margin flow [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Ichor on behalf of stockholders who may have suffered losses [1][3]. - The investigation focuses on whether Ichor has engaged in unlawful business practices or violated federal securities laws [1].

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EchoStar Corporation (“EchoStar” or the “Company”) (NASDAQ:SATS) on behalf of EchoStar stockholders. Our investigation concerns whether EchoStar has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 12, 2025, The Wall Street Journal reported that the Federa ...

Group 1 - Iovance Biotherapeutics reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million compared to $73.7 million in the previous quarter [2] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [2] - The revenue guidance revision was attributed to recent launch dynamics of the T cell immunotherapy, Amtagvi® (lifileucel), which was launched in the U.S. in the first half of 2024 [2] Group 2 - Following the announcement of the financial results and guidance revision, Iovance's stock experienced a drop on unusually heavy trading volume [2] - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance on behalf of stockholders regarding possible violations of federal securities laws and unlawful business practices [1]

Core Viewpoint - Cleveland-Cliffs Inc. is facing scrutiny for potential violations of federal securities laws following a disappointing financial report and operational changes [1][2]. Financial Performance - Cleveland-Cliffs reported an adjusted loss that was larger than expected for Q1 2025, with a year-over-year revenue decline of 11%, totaling $4.63 billion [2]. - The company's share price fell from $8.49 to $7.15 following the announcement of its financial results [2]. Operational Changes - The company plans to fully or partially idle six steel plants due to negative impacts from underperforming non-core assets and lower index prices experienced in late 2024 and early 2025 [2]. - Cleveland-Cliffs is repositioning its portfolio to focus more on the automotive industry, moving away from non-core markets such as rail, high-carbon sheet, and specialty plate products [2].